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Simple Summary: Loss of the cells which secrete insulin, the hormone which controls blood sugar
levels, can occur due to the damaging effects of high levels of sugar and fat in the bloodstream, and is
a key factor which triggers type 2 diabetes. Protection against this damage is provided by one of the
fat and protein complexes which carry the ‘good’ cholesterol in the bloodstream, a complex which is
called high-density lipoprotein. This study looks at the changes in the expression of small pieces of
RNA, called microRNA, triggered in insulin-secreting cells by treatment with high density lipoprotein.
These small RNA sequences can help to regulate the expression of genes which can contribute to the
protective effect of high-density lipoproteins. Delivery of one of these sequences was able to modulate
gene expression in cells, but could not provide enough protection against the damaging effects of
high sugar and fat. We conclude that the complex changes in numerous microRNA sequences caused
by high density lipoproteins cannot be replicated by a single sequence, suggesting that networks of
regulatory microRNA sequences are more important than single sequences. The results will inform
drug discovery strategies which focus on high density lipoprotein and microRNA.
Abstract: High-density lipoproteins provide protection against the damaging effects of glucolipo-
toxicity in beta cells, a factor which sustains insulin secretion and staves off onset of type 2 diabetes
mellitus. This study examines epigenetic changes in small non-coding microRNA sequences induced
by high density lipoproteins in a human hybrid beta cell model, and tests the impact of delivery
of a single sequence in protecting against glucolipotoxicity. Human PANC-1.1B4 cells were used
to establish Bmax and Kd for [3H]cholesterol efflux to high density lipoprotein, and minimum
concentrations required to protect cell viability and reduce apoptosis to 30mM glucose and 0.25 mM
palmitic acid. Microchip array identified the microRNA signature associated with high density
lipoprotein treatment, and one sequence, hsa-miR-21-5p, modulated via delivery of a mimic and
inhibitor. The results confirm that low concentrations of high-density lipoprotein can protect against
glucolipotoxicity, and report the global microRNA profile associated with this lipoprotein; delivery
of miR-21-5p mimic altered gene targets, similar to high density lipoprotein, but could not provide
sufficient protection against glucolipotoxicity. We conclude that the complex profile of microRNA
changes due to HDL treatment may be difficult to replicate using a single microRNA, findings which
may inform current drug strategies focused on this approach.
Keywords: glucolipotoxicity; beta-cells; high density lipoprotein; microRNA; hsa-miR-21-5p
1. Introduction
The ‘pre-diabetic’ condition is characterised by insulin resistance, which eventually
triggers beta cell failure, loss of compensatory insulin secretion and the onset of frank
type 2 diabetes. Beta cell damage can be induced by glucolipotoxicity (GLT) [1], which
describes the deleterious effects of elevated levels of free fatty acids (FFA) on glucose
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homeostasis, resulting in concurrent, and synergistically damaging, exposure of beta-cells
to high glucose levels. Pleiotropic outcomes triggered in beta cells by high glucose/FFA
conditions, include oxidative stress, mitochondrial dysfunction, endoplasmic reticulum
(ER) stress, inflammation, impaired autophagy and loss of glucose-stimulated insulin se-
cretion, reflecting alterations in multiple cell signalling pathways [2], enhanced expression
of pro-inflammatory, lipogenic and pro-apoptotic genes and proteins [3], and accumulation
of lipids such as ceramides, cholesterol and cholesteryl esters and triacylglycerols [2–4].
By contrast, high-density lipoprotein (HDL) [5–8], its major apolipoprotein (apo),
apoA-I [7,9–11], and/or the ATP binding cassette (ABC) transporters with which they
interact [12–16], can provide protection to beta cells and pancreatic islets in experimental
models, findings generally supported by clinical data [17–21]. Studies variously link
these protective functions with sterol removal or efflux from beta cells [8,12–16]; others
report cholesterol- and/or transporter-independent effects of apoA-I and HDL [7,10],
while conflicting reports exist regarding beta cell function in carriers of loss of function
(LOF) mutations in ABCA1 [22,23]. Some of these divergent outcomes may be attributed
to the heterogeneous nature of HDL and its cargo molecules [24,25], and to the widely
differing concentrations of apoA-I (10 µg protein mL−1 to 900 µg mL−1) and/or HDL
(50 µg protein mL−1 to 1 mg mL−1) used, or required, to demonstrate the protective effect
of this lipoprotein in human and rodent beta cell models (reviewed in [5]).
Certainly, numerous cell signalling pathways are altered in beta cells by exposure
to apoA-I and HDL, including G protein coupled receptor (GPCR) activation of adenyl
cyclase, protein kinase A and forkhead box protein 01 (Fox01) [9], calcium signalling [7],
and activation of hedgehog (Hh) receptor Smoothened (SMO) [8], protein kinase B [26]
and sphingosine-1-phosphate receptors (S1PR1-3) [5,24,27]. Transcription factors, such
as the Liver X receptor (LXR), peroxisome proliferator activator receptor alpha (PPARα),
FOXO1 and BTB domain and CNC homolog 1 (BACH1) have also emerged as key factors
orchestrating cellular responses to fatty acids such as palmitate [3]. Further, in the last
decade, there has been an explosion of interest in the epigenetic mechanisms, including the
role of microRNA sequences, involved in beta cell (dys)function and type 2 diabetes [28].
MicroRNA are small, non-coding (~22 nucleotide) sequences which can regulate networks
of protein expression by binding to complementary mRNA binding regions, resulting in
either mRNA degradation or translational inhibition [28].
However, the epigenetic mechanisms that contribute to the protective effects of apoA-I
and HDL in human beta cells remain relatively uncharacterised. This study establishes, by
microchip array, the microRNA signature associated with apoA-I and HDL treatment in
human hybrid (1.1B4) pancreatic beta cells, at concentrations of these acceptors that induce
cholesterol efflux; after validation of the microchip array, the ability of a single microRNA
sequence, hsa-miR-21-5p, to protect against GLT was then investigated in the presence or
absence of HDL.
2. Materials and Methods
2.1. Cell Culture and Maintenance
Human PANC-1.1B4/human beta cell hybrid 1,1B4 cells (1.1B4 cells) were obtained
from Public Health England Culture Collections (#10012801). This cell line was generated
by electrofusion of human pancreatic beta cells and the immortal human PANC-1 epithelial
cell line, characterised by McCluskey et al. (2011) [29], and recently employed by Nemecz
et al. (2019) [30] to study glucolipotoxicity, and by Honkimaa et al. (2020) to study
genetic adaptation of Coxsackievirus B1 [31]. This human cell line was selected for this
study as human and rodent microRNA sequences and targets are not always conserved;
however, please note that this cell line has recently been discontinued (ECACC) due
to possible contamination with rat DNA (https://www.phe-culturecollections.org.uk/
products/celllines/discontinued-ecacc-cell-lines/11b4.aspx accessed on 20 January 2021).
The cells were maintained in ‘complete’ RPMI 1640 media (Lonza, Basel, Switzer-
land) containing foetal bovine serum (FBS, 10%, v/v; Gibco, Thermo Fisher Scientific,
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Waltham, MA, USA)and penicillin/streptomycin (50 U mL−1; 50 µg mL−1, respectively;
Gibco, Thermo Fisher Scientific, Waltham, MA, USA), at 37 ◦C and 5% CO2. Cells were
sub-cultured at 80% confluency at a ratio of 1:4 to 1:8, every 3–4 days, and utilised be-
tween passages 29 and 42. Experiments using apo(lipo)proteins, apoA-I and high-density
lipoprotein (HDL) (Athens Research & Technology, Athens, GA, USA), were performed in
serum-free RPMI media supplemented with penicillin/streptomycin, as described above.
2.2. Cellular Lipid Extraction and Analysis
Cholesterol efflux (0–24 h; 2.5 × 105 cells/well in a 12-well plate) was determined
in serum-free media, in the presence and absence of apoA-I (0.5–20 µg mL−1) or HDL
(0.5–80 µg mL−1) in cells previously radiolabelled with [3H]cholesterol (1 µCi mL−1; Perkin
Elmer, Beaconsfield, UK) for 20 h, and then equilibrated (18 h) in media containing 1.0%
(w/v) fatty acid free bovine serum albumin (BSA; Sigma Aldrich, Gillingham, UK). Lipids
were extracted from cells using hexane:isopropanol (3:2, v/v) and dried at 37 ◦C under a
stream of N2. Efflux was calculated as % Efflux = (dpm media)/(dpm media + dpm cells)
× 100%, as reported previously [32].
2.3. Glucolipotoxicity Assays
A working solution of 5mM palmitic acid conjugated with 10% (w/v) fatty acid free
BSA was diluted to the appropriate concentration in serum-free RPMI 1640, and glucose
added from a 1 M stock to achieve a final concentration of 30mM. Cell viability (2.5 × 104
cells/well in a 96-well plate) was measured by conversion of thiazolyl blue tetrazolium
bromide to formazan [33] and using the PrestoBlue cell viability assay (Thermo Fisher
Scientific, Waltham, MA, USA) [34]. CellEvent Caspase-3/7 Green Detect Reagent (Thermo
Fisher Scientific, Waltham, MA, USA) was used to monitor apoptosis [35].
2.4. Total RNA Isolation, Microchip Analysis and Q-PCR
Total RNA (5 × 105 cells/well in a 12-well plate) was collected using either a Direct-
zol RNA MiniPrep Plus kit (Zymo Research, Cambridge, UK) or a Nucleospin RNA kit
(Machery-Nagel, Düren, Germany). Complementary DNA (cDNA) used for measurement
of gene expression (mRNA) was generated from 250 ng RNA using the High-Capacity
cDNA Reverse Transcription kit (Applied Biosystems, Thermo Fisher Scientific, Waltham,
MA, USA) according to manufacturer’s instructions; cDNA used to measure miRNA
and/or mRNA was generated using the miScript II RT kit (Qiagen, Manchester, UK) and
HiFlex buffer, as indicated by the manufacturer.
Microarray analysis of miRNA expression was performed commercially by LC Sci-
ences (Houston, TX, USA); 2632 unique mature human miRNA sequences derived from ver-
sion 22 of miRBase [36] were measured using µParaflo microfluidic chip technology (https:
//www.lcsciences.com/discovery/applications/transcriptomics/mirna-profiling/mirna/
accessed on 3 January 2018), exemplified by Zhang et al. (2019) [37]. Relative quantita-
tive PCR (Q-PCR) for miRNA and mRNA expression was performed using the primer
sequences defined in Tables S1 and S2 (Supplementary Data) using HOT FIREPol EvaGreen
qPCR Mix Plus (Solis BioDyne) on a C1000 thermal cycler with a CFX96 real-time system
attached; melt curves were performed for all primers and none evidenced dimer formation.
The expression of target miRNA and mRNA was determined using the 2−∆∆Ct method
relative to an invariant control sequence/gene, as indicated in legends to figures; statistical
analyses were performed using the ∆Ct values, compared with the relevant housekeeping
sequence.
2.5. Transfection with miRNA Mimics and Inhibitors
Transfection of 1.1B4 cells (2 × 105 cells/well in a 12-well plate) with the hsa-miR-
21-5p mimic, and scrambled mimic control (Qiagen), and the miR-21-5p inhibitor and
scrambled inhibitor control (Qiagen) was achieved using HiPerFect Transfection Reagent
(Qiagen), according to the manufacturer’s instructions. In brief, transfection complexes
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(100 µL) were added in serum-free RPMI 1640 and incubated for 4h prior to the addition
of further serum-free RPMI 1640 (400 µL). The cells were incubated at 37 ◦C and 5% CO2
with the concentrations of mimic and inhibitor, and for the periods of time, indicated in
figure legends.
2.6. Bioinformatic Analysis
MicroRNA sequences differentially expressed after treatment with apoA-I and HDL,
compared with the basal control, were analysed using DNA Intelligent Analysis (DIANA)-
miRPath v3.0 [38,39] to identify pathways with p < 0.01 association with differentially ex-
pressed genes. Upregulated and downregulated miRNAs were analysed separately in miR-
Path; this utilized experimentally validated miRNA interactions in DIANA-TarBase v7.0
database [35] incorporated into Kyoto Encyclopedia of Genes and Genomes (KEGG) [40]
pathways to identify the most closely associated functions with each group. Disease-
specific pathways were excluded from the results. Interaction networks were created using
Cytoscape v3.8.0 [41]. The graphical abstract was created using Biorender.com.
2.7. Statistical Analysis
All datasets and methodologies were deposited in Mendeley Data (doi:10.17632/
s3bznmgtpg.1). Results are expressed as means ± SD or SEM of the number of experiments
indicated in legends to figures. Statistical analysis was performed by one-way, two-way, or
three-way ANOVA and Dunnett’s post-test, repeated measures ANOVA and Dunnett’s
post-test, or Student’s t test, as indicated in legends to figures. All statistical testing was
performed using Graph Pad Prism software; * p < 0.05; ** p < 0.01 and *** p < 0.001.
3. Results
3.1. Cholesterol Efflux from 1.1B4 Cells
Functional responses to apoA-I and HDL in 1.1B4 cells were established by measure-
ment of [3H]cholesterol efflux to these acceptors, shown in Figure 1. Efflux to apoA-I
(Figure 1A) was relatively low (estimated Bmax = 0.99 ± 0.15%) and plateaued (Kd = 3.70
±1.84 µg mL−1), with significant increases in efflux above the control condition noted at 10
and 20 µg mL−1. By contrast, efflux to HDL (Figure 1B) exhibited a curvilinear relationship,
with a substantially higher estimated Bmax (37.75 ± 3.69%) and Kd (77.66 ±12.78 µg mL−1);
concentrations of HDL (5–80 µg mL−1) significantly increased [3H]cholesterol efflux above
control. The levels of mRNA for ABCA1, which effluxes cholesterol to apoA-I, and of
ABCG1, which effluxes to HDL, were measured: gene expression (2−∆Ct; mean ±SEM) for
ABCA1, relative to PPIA, was 2.01 × 10−5 ± 1.25 × 10−5 (n = 3), while levels of ABCG1
relative to PPIA were 4.77 × 10−5 ± 3.6 × 10−5 (n = 3); equivalent primer efficiencies
were noted here (102% and 97%, respectively). These values are not significantly different,
suggesting that the activity and stability of these proteins contribute to the efflux outcomes
observed. Over time, [3H]cholesterol efflux to apoA-I (20 µg mL−1) and HDL (20 µg mL−1)
adhered strictly to linearity (Figure 1C) with highly significant (p < 0.001) differences noted
between the slope of each curve.
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Figure 1. The dose dependencies of [3H]cholesterol efflux to apoA-I (24 h) and HDL (24 h) are shown
in (A,B), resp ctively. The data were analysed using repeated measures ANOVA with post hoc
test (Dunnett’s) compared to the 0 µg mL−1 m as rement; * p < 0.05, ** p < 0.01 and *** p < 0.001.
Values are the mean ± SD of three independent experiments (each performed in triplicate). The time
dependency of [3H]cholesterol efflux under basal conditions, and to apoA-I (20 µg mL−1) and HDL
(20 µg mL−1) is shown in (C). The data was analysed using two-way ANOVA with post hoc test
(Dunnett’s) compared to the 0h timepoint; * p < 0.05, *** p < 0.001. Values are the mean ± SD of
between three and four independent experiments (each performed in triplicate). Standard deviations,
instead of SEM, have been shown, as the SEM for (B,C) are too small to be viewed.
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3.2. Glucolipotoxicity in 1.1B4 Cells
The impact of treatment with high glucose (30 mM) combined with a palmitic acid
(PA)/BSA complex (0.1 mM to 0.5mM PA) on the viability of 1.1B4 cells over 24 h is shown
in Figure 2A. No significant changes in viability due to any of these treatments were noted
at 0 h, as judged by conversion of MTT to formazan (data not shown); however, significant
reductions in viability were noted after 24 h at concentrations of 0.25 mM PA (43.4%; p <
0.05) and 0.5 mM PA (72.6%; p < 0.01), compared with the control incubation. The effect of
high glucose in combination with 0.25 mM PA on 1.1B4 cell viability was also confirmed
via cellular reduction of resazurin to fluorescent resorufin (47%; p < 0.001) (Figure 2B).
Addition of apoA-I at concentrations of 40 and 80 µg mL−1 (8 µM to 16 µM) significantly
increased cell viability, as judged by conversion of MTT to formazan, by 1.15-fold (p < 0.05)
and 1.19-fold (p < 0.01), respectively. However, delivery of ApoA-I at 20–80 µg mL−1 did
not protect against glucotoxicity enhanced by 0.25 mM PA (Figure 2C). By contrast, the
addition of HDL at 40 and 80 µg mL−1 (~0.05 mM to 0.1 mM HDL-cholesterol) increased
conversion of MTT to formazan by 1.68-fold (p < 0.05) and 2.33 fold (p < 0.001), compared
with the GLT challenge alone (Figure 2D).
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viability of 1.1B4 cells, as judged by conversion of MTT to formazan in four independent experiments (mean ± SEM),
normalised to the basal condition, is shown in (A). Data were analysed by one-way ANOVA with post hoc tests compared
to the basal group * p < 0.05, ** p < 0.01. The effect of 0.25 mM PA, under the same conditions, measured by conversion of
resazurin to fluorescent resorufin, is shown in (B); values are the mean ± S.D. of eight independent replicates in a single
experiment; the data were analysed by Students’ t-test; *** p < 0.001. The impact of apoA-I (0–80 µg mL−1) on the viability
of 1.1B4 cells under GLT challenge is shown in (C) (mean ± SEM; n = 3); the data ere analysed by two-way ANOVA with
post hoc test (Dun ett’s) compared to the basal group in the absence of apoA-I * p < 0.05, *** p < 0.0 1. The effect of HDL
(0–80 µg mL−1) un er the sa e conditions is shown in (D) (mean ± SE ; n = 3). The data were analysed by two-way
ANOVA with post hoc test (Dunnett’s) compared to the basal group in the absence of HDL. ### p < 0.001 compared with the
GLT challenge alone, or *** p < 0.001 compared with the GLT challenge alone.
Further, in the more sensitive resorufin cell viability assay, 20 µg protein mL−1 HDL
(~0.025 mM HDL-cholesterol) significantly improved cell viability by 1.38-fold (p < 0.01)
Biology 2021, 10, 218 7 of 17
under the same conditions (Figure 3A). Accordingly, this lowest concentration of HDL was
tested for its impact on cellular apoptosis (Figure 3B): analysis by two-way ANOVA indicate
a significant effect of time in all four conditions tested (p < 0.001) and no significant overall
effect of HDL. There was a significant interaction between time and HDL treatment (p <
0.001), with HDL significantly reducing apoptosis due to GLT challenge, under serum-free
conditions.
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GLT challeng (0.25 mM PA and 30mM) g ucose is shown in (A); results are the mean ± SEM of
4 independent experiments, analysed by n -way ANOV with post hoc (Dunnett’s) test for the
comparisons indicated: ** p < 0.01 and *** p < 0.001. The ability of the same concentration of HDL to
protect against GLT-induced apoptosis in 1.1B4 cells, measured by caspase3/7 activation, is shown
in (B); values are the mean ± SEM of 4 independent replicates in a single experiment. Statistical
analysis was performed using repeated measures ANOVA with post hoc (Dunnett’s) test compared
to the basal condition; * p < 0.05 and compared to GLT challenge alone: # p < 0.05 and ## p < 0.01
compared at the time points indicated.
3.3. Changes in microRNA Expression Due to apoA-I and HDL in 1.1B4 Cells
Figure 4 shows the changes in microRNA expression detected by a global, unbiased
microchip analysis after exposure of 1.1B4 cells to 20 µg mL−1 ApoA-I, or the equivalent
concentration of HDL, for 24 h; the full report of all sequences analysed for Figure 4
has been deposited in Mendeley (doi:10.17632/s3bznmgtpg.1). Sequences common to
both treatments include significant elevations in hsa-miR-25-3p and hsa-miR-29a-3p, and
reductions in hsa-miR-30e-5p, hsa-miR-146a-5p and hsa-miR-335-3p. Equally, a number
of miR sequences appear regulated selectively by HDL treatment, including increased
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expression of hsa-miR-21-5p and hsa-miR-7977, and loss of expression of hsa-miR-15b-5p,
hsa-miR-16-5p, hsa-miR-130a-3p and hsa-miR-191-5p.
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particular interest as this sequence and it targets have been associated with increased pro-
liferation and reduced apoptosis [42–46], beta cell number and function [47–49] and the 
aetiology of diabetes [50–54]. Consequently, HDL-induced changes in miR-21-5p expres-
sion noted in the microchip array were confirmed by Q-PCR (Figure 5A): using this meth-
odology, an increase due to HDL (63%; p < 0.05), but not apoA-I, was noted. Treatment 
Figure 4. Heatmaps depicting miRNAs that are differentially expressed following a 24 h treatment with 20 µg mL−1.ApoA-I
(A) or 20 µg mL−1 L ( ). ata are presented fro 1 sa ple per group each ith an independent icrochip array
significant iR s.
ele ation of hsa-miR-21-5p in 1.1B4 cells d tected by microchip nalyses was
of particular intere t as this s qu nce and it targets hav been associated with increased
proliferation an reduced apoptosis [ 2–46], beta cell number and function [47–49] and
the aetiol gy of diabetes [50–54]. Consequently, HDL-induced changes in miR-21-5p
expression oted in the microchip ar ay were confirmed by Q-PCR (Figure 5A): using this
methodology, an increase due to HDL (63%; p < 0.05), but not apoA-I, was noted. r t t
with HDL also reduced expression of two out of five predicted (miRBase 22) gene targets
of miR-21-5p, ZNF367 (87%; p < 0.05), SMAD7 (33%; p < 0.05) and STAT3 (23%; p < 0.05)
(Figure 5B), but not PDCD4 or FOXO3. Transient delivery (24 h) of a miR-21-5p mimic
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(5 nM) to the 1.1B4 cell line (Figure 5C) achieved a 37% (p < 0.01) increase in levels of this
sequence, and significant reductions in expression of SMAD7 (26%; p < 0.05) and STAT3
(31%; p < 0.01), but not of the other target genes investigated. By contrast, delivery of
a miR-21-5p inhibitor (10 nM) achieved a 21% (p < 0.05) reduction in the expression of
miR-21-5p, but did not significantly increase target gene expression (Figure 5D).
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3.4. Hsa-miR-21-5p and Glucolipotoxicity in 1.1B4 Cells
The effect of the miR-21-5p mimic and inhibitor on the viability of 1.1B4 cells, in the
presence and absence of HDL, is shown in Figure 6. Transfection with the control, mimic
or inhibitor did not alter cell viability compared with the wild type cells; neither the mimic
(Figure 6A) or the inhibitor (Figure 6B) could alter the impact of the GLT challenge on
the viability of 1.14 cells, compared with the relevant control. The effect of the miR-21-5p
inhibitor, in the presence of HDL in the GLT challenge, is shown in Figure 6C; the protective
effect of HDL was sustained under transfection conditions, but was not altered by the
presence of the miR-21-5p inhibitor, despite the established anti-apoptotic effects of this
miRNA sequence [28].





  Figure 6. The influence of 5 nM miR-21-5p mimic or 10 nM miR-21-5p inhibitor on the response of 1.1B4 cells to GLT
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experiments, analysed by two-way ANOVA and post hoc (Dunnett’s) test *** p < 0.001. The effect of the miR-21-5p inhibitor
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3.5. Pathways Targeted by microRNA Sequences Altered by HDL Treatment
Bioinformatic analysis via miRPath v3.0 showed that 18 KEGG pathways were associ-
ated with miRNAs downregulated by 20 µg mL−1 HDL (hsa-miR-30e-5p, hsa-miR-146a-5p,
hsa-miR-130a-3p, hsa-miR-181a-5p, hsa-miR-15b-5p, hsa-miR-335-5p, hsa-miR-425-5p, hsa-
miR-16-5p, hsa-miR-340-5p and hsa-miR-191-5p) (Figure 7A) and 13 KEGG pathways
were associated with upregulated miRNAs (hsa-miR-7977, hsa-miR-25-3p, hsa-miR-29a-3p
and hsa-miR-21-5p) (Figure 7B). miR-7977 did not contribute to the analysis as there are
no interactions documented in TarBase. Pathways such as fatty acid biosynthesis and
metabolism were common to downregulated miRNAs, and upregulated by treatment
with HDL. Nine KEGG pathways were unique to downregulated miRNAs, including the
TGF-beta signalling pathway (p = 3.71 × 10−9) and protein processing in the endoplasmic
reticulum (p = 2.48 × 10−7). Four pathways were unique to miRNAs upregulated by HDL,
including the FoxO signalling (p = 1.99 × 10−3) and fatty acid elongation (p = 7.43 × 10−5)
pathways.





Figure 7. The KEGG pathways strongly associated with the miRNAs differentially expressed following 20 µg mL−1 HDL
(24 h) treatment were identified through bioinformatics analyses using miRPath v.3.0. Ten downregulated miRNAs and
4 upregulated miRNAs were used for analysis. Pathways associated with downregulated or upregulated miRNAs are
presented in (A,B), respectively. Pathways are ranked, in order of the most closely associated pathways.
4. Discussion
This study demonstrates the protective effects of HDL, at concentrations below those
required for transporter saturation but which sustain linear cholesterol efflux, in 1.1B4
cells subject to a GLT challenge. These well-characterised conditions induce a network
of changes in miRNA sequences, as determined by microchip array, including increased
expression of miR-21-5p which mediates anti-apoptotic effects [28]. Delivery of a miR-21-
5p mimic replicated the impact of HDL on gene expression of STAT3 (signal transducer
and activator of transcription 3) and SMAD7 (decapentaplegic protein 3), two established
targets of this sequence; no changes in expression of STAT3 and SMAD7 were induced by
delivery of miR-21-5p inhibitor. However, neither the mimic nor the inhibitor, the latter in
the presence or absence of HDL, could significantly change the response of 1.1B4 cells to a
GLT challenge. The data suggest that the complex epigenetic changes induced by HDL
in human beta cells is unlikely to be replicated by a single miRNA sequence, supporting
the emerging concept that global changes in miRNA networks may be more biologically
relevant than changes in a single sequence [55].
Exposure to HDL has previously been linked with epigenetic changes in microRNA
in a number of differing cell types [56], but this is the first report of the impact of these
(apo)lipoproteins in an in vitro human beta cell model; equally, a number of microRNA
sequences have been linked with (dys)function of beta cells [28]. Examination of these
literature, compared with the microchip array reported here (Figure 4) reveal some common
sequences [28,47,48,55–58]. For example, miR-21 has been shown to target Snc2, decreasing
Vamp2 and GSIS, but also to significantly modulate apoptosis in a range of rodent and
human islet cell lines and tissues [28,48,49]. Mir-29 has been linked with increases in
insulin exocytosis, but also with increased apoptosis via reductions in Mcl1 [28]; miR-
130 and miR-335 exert opposing actions on GSIS, while miR-146a is thought to increase
apoptosis by increased expression of c-Jun [28,47–49]. However, treatment with HDL also
alters expression of other sequences, not previously linked to maintenance of beta cell
function [55,59]. Some have no function ascribed to them at present (hsa-miR-15b-5p,
hsa-miR-181a-5p, hsa-miR-426-5p) while hsa-miR-16-5p was found to be down-regulated
after bariatric surgery in obese patients [49], and hsa-miR-191-5p emerged as differentially
regulated in Alzheimer’s disease and major depressive disorder [58].
Delivery of the miR-21-5p mimic significantly altered the level of this sequence in
1.1B4 cells, to a similar extent as HDL treatment, exerting comparable reductions in gene
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expression of its established target genes STAT3 and SMAD7, indicating that the mimic
was effective in this cell type. High density lipoprotein has previously been linked with
activation of the pro-survival STAT3 signalling pathway [59,60], which protects against
inflammation and apoptosis in many cell types [59–63]. However, Zeng et al. (2017) found
that inhibition of expression and phosphorylation of STAT3 in hepatic cells restored insulin
sensitivity in mice fed a high fat diet [64], while inhibition of the STAT3 pathway has
also been linked with reductions in murine arterial atherosclerosis [65]. Repression of
SMAD7 has not previously been reported after HDL treatment, but this protein is a well-
established inhibitor of the TGFβ signalling pathway which regulates fibrosis, inflammation
and wound healing and cancer, and loss of Smad7 in mice is associated with enhanced
cell proliferation and reduced apoptosis [66]. Thus, it is clear that multiple molecular
mechanisms may underlie the overall impact of HDL on apoptosis [28].
Indeed, the function of miR-21-5p in beta cells also needs careful consideration. Many
studies indicate an anti-apoptotic role for this sequence in differing cell types and via a
variety of mechanisms [42–46]. In particular, knockdown of miR-21 increases translation of
proinflammatory tumour suppressor programmed cell death protein 4 (PDCD4), restricts
cell proliferation and promotes apoptosis, while high levels of miR-21 are associated
with cancer [42]. It is therefore possible that the elevation in miR-21-5p due to HDL
may contribute to survival of 1.1B4 cells, via a mechanism which is not affected by gene
repression of STAT3 but could be aided by reduction in expression of SMAD7 (Figure 5).
However, it is clear that the transient (and modest) increase in miR-21-5p levels due to the
presence of the mimic alone was not sufficient to prevent the loss of viability due to GLT
challenge, and nor could the inhibitor block the protective impact of HDL in this cell line
under the same conditions (Figure 6). Ruan et al. (2011) reported that elevated levels in
miR-21, which induces a deficiency in PDCD4, can inhibit nuclear factor-kB (NF-κB) and
protect beta-cells against streptozotocin-induced cell death, and spontaneous autoimmune
diabetes in non-obese diabetic mice and C57BL7 mice [57,58]. Pro-inflammatory cytokines
induce the expression of miR-21 [48], and Backe et al. (2014) suggested this is a protective
response to preserve beta cell viability [47]. The feasibility of miR-21-5p as a pro-survival
therapeutic agent, however, has been cast into doubt by the finding that stable (long-term)
expression of miR-21-5p not only increased the proliferation of rat INS-1 insulinoma cells,
but also stimulated nitric oxide synthesis and apoptosis [28,64].
Analysis by miRPath established numerous KEGG pathways associated with miRNAs
differentially expressed in 1.1 beta cells following exposure to HDL (Figure 7). Three
pathways that were linked to mRNAs down- or upregulated by HDL were fatty acid
biosynthesis, fatty acid metabolism and lysine degradation, previously linked to the role
of HDL in reverse cholesterol transport [67]. Additional pathways, including the Hippo
signalling pathway, extracellular matrix (ECM)-receptor interactions and thyroid hormone
signalling suggest a role for HDL in regulating developmental processes in beta cells. It is
understood that miRNAs are involved in maturation of beta cells and maintenance of beta
cell identity with miR-7, miR-9, miR-375, miR-376, miR-17-5p and miR-29b-3p examined
in this context [68,69]. In conjunction with identification of adherens junction, cell cycle
and p53 signalling pathways, this suggests that HDL modulate pathways in beta cells that
control responses to stress, cell proliferation and apoptosis, supporting our observations
that HDL protect 1.1B4 beta cells from damage due to GLT challenge. Two KEGG pathways
uniquely linked to miRNAs upregulated by HDL were also associated with miR-21-5p
(Figure 8): fatty acid elongation and the FoxO signalling pathway. Notably, the FoxO
signalling pathway integrates a number of signalling pathways such as TGF-beta, PI3K-
Akt and Jak-STAT, to regulate functions including cell metabolism, cell cycle regulation
and apoptosis [70,71].




Figure 8. Interaction networks between miRNAs differentially expressed following 20 µg mL−1 HDL treatment and their
associated pathways were produced in Cytoscape v3.8.0. Ten downregulated miRNAs and 4 upregulated miRNAs were
used for analysis. The interaction networks depicting miRNA-pathway connections for downregulated and upregulated
miRNAs are presented in (A,B), respectively. The networks are annotated so that the size of the pathway labels are
proportional to the number of genes in the network associated with the relevant miRNAs and the thickness of the edges
corresponds to the proportion of the total miRNA:gene interactions in each pathway.
If we consider the limitations of this study, there are several points to note. One
key point is that the study is restricted to use of the 1.1B4 cell line (with the associated
drawbacks discussed above): replication in primary human islet beta cells would provide
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greater impact to the findings. Further, the use of metabolic activity assays (MTT and
resorufin conversion) as measures of cell viability, and of caspase 3/7 activity as a measure
of apoptosis, do not provide insight into the mechanism(s) by which HDL protect the 1.1B4
cells from a GLT challenge. Finally, the analysis of microRNA sequences altered by HDL
treatment, compared with the control, derive from single samples using three technical
replicates on each microchip, albeit validated in three independent experiments by Q-PCR.
5. Conclusions
This study observed that low concentrations of HDL protect 1.1B4 beta cells from
the reduction in cell viability, and increased apoptosis, induced by challenge with 30 mM
glucose and 0.25 mM palmitic acid (GLT). Analysis by microchip array following exposure
to HDL demonstrated differentially expressed miRNAs which were associated with KEGG
pathways linked with beta cell development, cell proliferation and apoptosis. Hsa-miR-21-
5p upregulation by HDL was validated by qPCR and shown to lead to downregulation
of SMAD7 and STAT3. Modulation of miR-21-5p by mimics and inhibitors also reduced
SMAD7 and STAT3 expression, however, this did not affect the deleterious effects of GLT
challenge on the 1.1B4 beta cells. We suggest that examination of the networks of miRNA
pathways regulated by HDL is necessary to understand the epigenetic regulation required
to simulate HDL protection of beta cells in developing future therapeutics.
Supplementary Materials: The following are available online at https://www.mdpi.com/2079-773
7/10/3/218/s1, Table S1: Primer sequences for qPCR to measure mRNA expression of the genes
specified, Table S2: Primer sequences for qPCR to measure hsa-miR-21-5p expression.
Author Contributions: Conceptualization, J.M.R.T., S.P. and A.G.; methodology, J.M.R.T. and R.J.L.;
validation, J.M.R.T., S.P. and A.G.; formal analysis, J.M.R.T. and A.G.; investigation, J.M.R.T.; re-
sources, A.G.; data curation, J.M.R.T.; writing—original draft preparation, A.G.; writing—review and
editing, J.M.R.T., R.J.L., S.P. and A.G.; visualization, J.M.R.T.; supervision, A.G.; project administra-
tion, A.G. All authors have read and agreed to the published version of the manuscript.
Funding: This research received no external funding. J.M.R.T. was supported by a Ph.D. scholarship
from Glasgow Caledonian University.
Institutional Review Board Statement: Not applicable.
Informed Consent Statement: Not applicable.
Data Availability Statement: The data presented in this study are openly available in Mendeley
Data at (doi:10.17632/s3bznmgtpg.1).
Acknowledgments: We thank the excellent technical team at Glasgow Caledonian University for
their expert assistance.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Prentki, M.; Corkey, B.E. Are the β-Cell Signaling Molecules Malonyl-CoA and Cystolic Long-Chain Acyl-CoA Implicated in
Multiple Tissue Defects of Obesity and NIDDM? Diabetes 1996, 45, 273–283. [CrossRef]
2. Lytrivi, M.; Castell, A.-L.; Poitout, V.; Cnop, M. Recent Insights Into Mechanisms of β-Cell Lipo- and Glucolipotoxicity in Type 2
Diabetes. J. Mol. Biol. 2020, 432, 1514–1534. [CrossRef] [PubMed]
3. Lytrivi, M.; Ghaddar, K.; Lopes, M.; Rosengre, V.; Piron, A.; Yi, X.; Johansson, H.; Lehto, J.; Iigoillo-Esteve, M.; Cunha, D.A.; et al.
Combined transcriptomic and proteome profiling of the pancreatic β-cell re-sponse to palmitate unveils key pathways of β-cell
lipotoxicity. BMC Genom. 2020, 21, 590. [CrossRef] [PubMed]
4. Fryirs, M.; Barter, P.J.; Rye, K.-A. Cholesterol metabolism and pancreatic beta-cell function. Curr. Opin. Lipidol. 2009, 20, 150–164.
[CrossRef] [PubMed]
5. Von Eckardstein, A.; Widmann, C. High-density lipoprotein, beta cells, and diabetes. Cardiovasc. Res. 2014, 103, 384–394.
[CrossRef] [PubMed]
6. Rutti, S.; Ehses, J.A.; Sibler, R.A.; Prazak, R.; Rohrer, L.; Georgopoulos, S.; Meier, D.T.; Niclauss, N.; Berney, T.; Donath, M.Y.;
et al. Low- and High-Density Lipoproteins Modulate Function, Apoptosis, and Proliferation of Primary Human and Murine
Pancreatic β-Cells. J. Endocrinol. 2009, 150, 4521–4530. [CrossRef] [PubMed]
Biology 2021, 10, 218 15 of 17
7. Fryirs, M.A.; Barter, P.J.; Appavoo, M.; Tuch, B.E.; Tabet, F.; Heather, A.K.; Rye, K.-A. Effects of High-Density Lipoproteins on
Pancreatic β-Cell Insulin Secretion. Arter. Thromb. Vasc. Biol. 2010, 30, 1642–1648. [CrossRef] [PubMed]
8. Yalcinkaya, M.; Kerksiek, A.; Gebert, K.; Annema, W.; Sibler, R.; Radosavljevic, S.; Luetjohann, D.; Rohrer, L.; von Eckardstein, A.
HDL inhibits endoplasmic reticulum stress-induced apoptosis of pancreatic β-cells in vitro by activation of Smoothened. J. Lipid
Res. 2020, 61, 492–504. [CrossRef]
9. Cochran, B.J.; Bisoendial, R.J.; Hou, L.; Glaros, E.N.; Rossy, J.; Thomas, S.R.; Barter, P.J.; Rye, K.-A. Apolipoprotein A-I Increases
Insulin Secretion and Production from Pancreatic β-Cells via a G-Protein-cAMP-PKA-FoxO1–Dependent Mechanism. Arter.
Thromb. Vasc. Biol. 2014, 34, 2261–2267. [CrossRef] [PubMed]
10. Hou, L.; Tang, S.; Wu, B.J.; Ong, K.-L.; Westerterp, M.; Barter, P.J.; Cochran, B.J.; Tabet, F.; Rye, K.-A. Apolipoprotein A-l improves
pancreatic β-cell function independent of the ATP-binding cassette transporters ABCA1 and ABCG1. FASEB J. 2019, 33, 8479–8489.
[CrossRef] [PubMed]
11. Nilsson, O.; Del Giudice, R.; Nagao, M.; Grönberg, C.; Eliasson, L.; Lagerstedt, J.O. Apolipoprotein A-I primes beta cells to
increase glucose stimulated insulin secretion. Biochim. Biophys. Acta (BBA) Mol. Basis Dis. 2020, 1866, 165613. [CrossRef] [PubMed]
12. Brunham, L.R.; Kruit, J.K.; Pape, T.D.; Timmins, J.M.; Reuwer, A.Q.; Vasanji, Z.; Marsh, B.J.; Rodrigues, B.; Johnson, J.D.; Parks,
J.S.; et al. β-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat. Med.
2007, 13, 340–347. [CrossRef] [PubMed]
13. Kruit, J.K.; Kremer, P.H.C.; Dai, L.; Tang, R.; Ruddle, P.; De Haan, W.; Brunham, L.R.; Verchere, C.B.; Hayden, M.R. Cholesterol
efflux via ATP-binding cassette transporter A1 (ABCA1) and cholesterol uptake via the LDL receptor influences cholesterol-
induced impairment of beta cell function in mice. Diabetology 2010, 53, 1110–1119. [CrossRef] [PubMed]
14. Kruit, J.K.; Wijesekara, N.; Fox, J.E.M.; Dai, X.-Q.; Brunham, L.R.; Searle, G.J.; Morgan, G.P.; Costin, A.J.; Tang, R.; Bhattacharjee,
A.; et al. Islet Cholesterol Accumulation Due to Loss of ABCA1 Leads to Impaired Exocytosis of Insulin Granules. Diabetes 2011,
60, 3186–3196. [CrossRef] [PubMed]
15. Wijesekara, N.; Zhang, L.-H.; Kang, M.H.; Abraham, T.; Bhattacharjee, A.; Warnock, G.L.; Verchere, C.B.; Hayden, M.R. miR-33a
Modulates ABCA1 Expression, Cholesterol Accumulation, and Insulin Secretion in Pancreatic Islets. Diabetes 2012, 61, 653–658.
[CrossRef]
16. Kruit, J.K.; Wijesekara, N.; Westwell-Roper, C.; Vanmierlo, T.; De Haan, W.; Bhattacharjee, A.; Tang, R.; Wellington, C.L.;
Lütjohann, D.; Johnson, J.D.; et al. Loss of Both ABCA1 and ABCG1 Results in Increased Disturbances in Islet Sterol Homeostasis,
Inflammation, and Impaired -Cell Function. Diabetes 2012, 61, 659–664. [CrossRef] [PubMed]
17. Dullaart, R.P.; Annema, W.; de Boer, J.F.; Tietge, U.J. Pancreatic β-cell function relates positively to HDL functionality in
well-controlled Type 2 diabetes mellitus. Atherosclerosis 2012, 222, 567–573. [CrossRef]
18. Bardini, G.; Dicembrini, I.; Rotella, C.M.; Giannini, S. Correlation between HDL cholesterol levels and beta-cell function in
subjects with various degree of glucose tolerance. Acta Diabetol. 2013, 50, 277–281. [CrossRef]
19. Zheng, S.; Xu, H.; Zhou, H.; Ren, X.; Han, T.; Chen, Y.; Qiu, H.; Wu, P.; Zheng, J.; Wang, L.; et al. Associations of lipid profiles
with insulin resistance and β cell function in adults with normal glucose tolerance and different categories of impaired glucose
regulation. PLoS ONE 2017, 12, e0172221. [CrossRef]
20. Kumar, H.; Mishra, M.; Bajpai, S.; Pokhria, D.; Arya, A.K.; Singh, R.K.; Tripathi, K. Correlation of insulin resistance, beta cell
function and insulin sensitivity with serum sFas and sFasL in newly diagnosed type 2 diabetes. Acta Diabetol. 2011, 50, 511–518.
[CrossRef]
21. Fiorentino, T.V.; Succurro, E.; Marini, M.A.; Pedace, E.; Andreozzi, F.; Perticone, M.; Sciacqua, A.; Perticone, F.; Sesti, G. HDL
cholesterol is an independent predictor of β-cell function decline and incident type 2 diabetes: A longitudinal study. Diabetes
Metab. Res. Rev. 2020, 36, e3289. [CrossRef] [PubMed]
22. Vergeer, M.; Brunham, L.R.; Koetsveld, J.; Kruit, J.K.; Verchere, C.B.; Kastelein, J.J.; Hayden, M.R.; Stroes, E.S. Carriers of
Loss-of-Function Mutations in ABCA1 Display Pancreatic -Cell Dysfunction. Diabetes Care 2010, 33, 869–874. [CrossRef] [PubMed]
23. Rickels, M.R.; Goeser, E.S.; Fuller, C.; Lord, C.; Bowler, A.M.; Doliba, N.M.; Hegele, R.A.; Cuchel, M. Loss-of-Function Mutations
inABCA1and Enhanced β-Cell Secretory Capacity in Young Adults. Diabetes 2014, 64, 193–199. [CrossRef]
24. Ertek, S. High-density Lipoprotein (HDL) Dysfunction and the Future of HDL. Curr. Vasc. Pharmacol. 2018, 16, 490–498. [CrossRef]
25. Plochberger, B.; Axmann, M.; Röhrl, C.; Weghuber, J.; Brameshuber, M.; Rossboth, B.K.; Mayr, S.; Ros, R.; Bittman, R.; Stangl, H.;
et al. Direct observation of cargo transfer from HDL particles to the plasma membrane. Atheroscler. 2018, 277, 53–59. [CrossRef]
26. Roehrich, M.-E.; Mooser, V.; Lenain, V.; Herz, J.; Nimpf, J.; Azhar, S.; Bideau, M.; Capponi, A.; Nicod, P.; Haefliger, J.-A.; et al.
Insulin-secreting β-Cell Dysfunction Induced by Human Lipoproteins. J. Biol. Chem. 2003, 278, 18368–18375. [CrossRef]
27. Kurano, M.; Hara, M.; Tsuneyama, K.; Sakoda, H.; Shimizu, T.; Tsukamoto, K.; Ikeda, H.; Yatomi, Y. Induction of insulin secretion
by apolipoprotein M, a carrier for sphingosine 1-phosphate. Biochim. et Biophys. Acta (BBA) Mol. Cell Biol. Lipids 2014, 1841,
1217–1226. [CrossRef] [PubMed]
28. Osmai, M.; Osmai, Y.; Bangberthelsen, C.H.; Pallesen, E.M.H.; Vestergaard, A.L.; Novotny, G.W.; Pociot, F.; Mandrup-Poulsen, T.
MicroRNAs as regulators of beta-cell function and dysfunction. Diabetes/Metabolism Res. Rev. 2016, 32, 334–349. [CrossRef]
29. McCluskey, J.T.; Hamid, M.; Guo-Parke, H.; McClenaghan, N.H.; Gomis, R.; Flatt, P.R. Development and functional character-
ization of insulin-releasing human pancreatic beta cell lines produced by electrofusion. J. Biol. Chem. 2011, 286, 21982–21992.
[CrossRef] [PubMed]
Biology 2021, 10, 218 16 of 17
30. Nemecz, M.; Constantin, A.; Dumitrescu, M.; Alexandru, N.; Filippi, A.; Tanko, G.; Georgescu, A. The Distinct Effects of Palmitic
and Oleic Acid on Pancreatic Beta Cell Function: The Elucidation of Associated Mechanisms and Effector Molecules. Front.
Pharmacol. 2019, 9, 1554. [CrossRef]
31. Honkimaa, A.; Kimura, B.; Sioofy-Khojine, A.-B.; Lin, J.; Laiho, J.; Oikarinen, S.; Hyöty, H. Genetic Adaptation of Coxsackievirus
B1 during Persistent Infection in Pancreatic Cells. Microorganisms 2020, 8, 1790. [CrossRef]
32. De la Llera Moya, M.; Atger, V.; Paul, J.L.; Fournier, N.; Moatti, N.; Giral, P.; Friday, K.E.; Rothblat, G. A cell culture system
for screening human serum for ability to promote cellular cholesterol efflux. Relations between serum components and efflux,
esterification, and transfer. Arter. Thromb 1994, 14, 1056–1065. [CrossRef] [PubMed]
33. Kumar, P.; Nagarajan, A.; Uchil, P.D. Analysis of Cell Viability by the MTT Assay. Cold Spring Harb. Protoc. 2018, 2018. [CrossRef]
34. Xu, M.; McCanna, D.J.; Sivak, J.G. Use of the viability reagent PrestoBlue in comparison with alamarBlue and MTT to assess the
viability of human corneal epithelial cells. J. Pharmacol. Toxicol. Methods 2015, 71, 1–7. [CrossRef] [PubMed]
35. Jeelani, R.; Chatzicharalampous, C.; Kohan-Ghadr, H.-R.; Bai, D.; Morris, R.T.; Sliskovic, I.; Awonuga, A.; Abu-Soud, H.M.
Hypochlorous acid reversibly inhibits caspase-3: A potential regulator of apoptosis. Free. Radic. Res. 2020, 54, 43–56. [CrossRef]
[PubMed]
36. Kozomara, A.; Birgaoanu, M.; Griffiths-Jones, S. miRBase: From microRNA sequences to function. Nucleic Acids Res. 2019, 47,
D155–D162. [CrossRef] [PubMed]
37. Zhang, S.; Wang, L.; Cheng, L. Aberrant ERG expression associates with downregulation of miR-4638-5p and selected genomic
alterations in a subset of diffuse large B-cell lymphoma. Mol. Carcinog. 2019, 58, 1846–1854. [CrossRef] [PubMed]
38. Vlachos, I.S.; Zagganas, K.; Paraskevopoulou, M.D.; Georgakilas, G.; Karagkouni, D.; Vergoulis, T.; Dalamagas, T.; Hatzigeorgiou,
A.G. DIANA-miRPath v3.0: Deciphering microRNA function with experimental support. Nucleic Acids Res. 2015, 43, W460–W466.
[CrossRef] [PubMed]
39. Vlachos, I.S.; Paraskevopoulou, M.D.; Karagkouni, D.; Georgakilas, G.; Vergoulis, T.; Kanellos, I.; Anastasopoulos, I.L.; Maniou, S.;
Karathanou, K.; Kalfakakou, D. DIANA-TarBase v7.0: Indexing more than half a million experimentally supported miRNA:mRNA
interactions. Nucleic Acids Res. 2014, 43, D153–D159. [CrossRef] [PubMed]
40. Kanehisa, M.; Goto, S.; Sato, Y.; Kawashima, M.; Furumichi, M.; Tanabe, M. Data, information, knowledge and principle: Back to
metabolism in KEGG. Nucleic Acids Res. 2014, 42, D199–D205. [CrossRef]
41. Shannon, P.; Markiel, A.; Ozier, O.; Baliga, N.S.; Wang, J.T.; Ramage, D.; Amin, N.; Schwikowski, B.; Ideker, T. Cytoscape: A
Software Environment for Integrated Models of Biomolecular Interaction Networks. Genome Res. 2013, 13, 2498–2504. [CrossRef]
[PubMed]
42. Liu, H.-Y.; Zhang, Y.-Y.; Zhu, B.-L.; Feng, F.-Z.; Yan, H.; Zhang, H.-Y.; Zhou, B. miR-21 regulates the proliferation and apoptosis of
ovarian cancer cells through PTEN/PI3K/AKT. Eur. Rev. Med Pharmacol. Sci. 2019, 23, 4149–4155. [PubMed]
43. Canfrán-Duque, A.; Rotllan, N.; Zhang, X.; Fernández-Fuertes, M.; Ramírez-Hidalgo, C.; Araldi, E.; Daimiel, L.; Busto, R.;
Fernández-Hernando, C.; Suárez, Y. Macrophage deficiency of miR-21 promotes apoptosis, plaque necrosis, and vascular
inflammation during atherogenesis. EMBO Mol. Med. 2017, 9, 1244–1262. [CrossRef]
44. Hao, X.-J.; Xu, C.-Z.; Wang, J.-T.; Li, X.-J.; Wang, M.-M.; Gu, Y.-H.; Liang, Z.-G. miR-21 promotes proliferation and inhibits
apoptosis of hepatic stellate cells through targeting PTEN/PI3K/AKT pathway. J. Recept. Signal Transduct. 2018, 38, 455–461.
[CrossRef]
45. Liu, Y.; Ren, L.; Liu, W.; Xiao, Z. MiR-21 regulates the apoptosis of keloid fibroblasts by caspase-8 and the mitochondria-mediated
apoptotic signaling pathway via targeting FasL. Biochem. Cell Biol. 2018, 96, 548–555. [CrossRef]
46. Zhou, B.; Wang, D.; Sun, G.; Mei, F.; Cui, Y.; Xu, H. Effect of miR-21 on Apoptosis in Lung Cancer Cell Through Inhibiting the
PI3K/ Akt/NF-κB Signaling Pathway in Vitro and in Vivo. Cell. Physiol. Biochem. 2018, 46, 999–1008. [CrossRef]
47. Ruan, Q.; Wang, T.; Kameswaran, V.; Wei, Q.; Johnson, D.S.; Matschinsky, F.; Shi, W.; Chen, Y.H. The microRNA-21-PDCD4
axis prevents type 1 diabetes by blocking pancreatic cell death. Proc. Natl. Acad. Sci. USA 2011, 108, 12030–12035. [CrossRef]
[PubMed]
48. Roggli, E.; Britan, A.; Gattesco, S.; Lin-Marq, N.; Abderrahmani, A.; Meda, P.; Regazzi, R. Involvement of MicroRNAs in the
Cytotoxic Effects Exerted by Proinflammatory Cytokines on Pancreatic -Cells. Diabetes 2010, 59, 978–986. [CrossRef]
49. Backe, M.B.; Novotny, G.W.; Christensen, D.P.; Grunnet, L.G.; Mandrup-Poulsen, T. Altering β-cell number through stable
alteration of miR-21 and miR-34a expression. Islets 2014, 6, e27754. [CrossRef] [PubMed]
50. Doghish, A.S.; Elsisi, A.M.; Amin, A.I.; Abulsoud, A.I. Circulating miR-148a-5p and miR-21-5p as Novel Diagnostic Biomarkers
in Adult Egyptian Male Patients with Metabolic Syndrome. Can. J. Diabetes 2021, 5, 1499. [CrossRef]
51. Guan, C.-Y.; Tian, S.; Cao, J.-L.; Wang, X.-Q.; Ma, X.; Xia, H.-F. Down-Regulated miR-21 in Gestational Diabetes Mellitus Placenta
Induces PPAR-α to Inhibit Cell Proliferation and Infiltration. Diabetes Metab. Syndr. Obes. Targets Ther. 2020, 13, 3009–3034.
[CrossRef]
52. Hromadnikova, I.; Kotlabova, K.; Dvorakova, L.; Krofta, L. Diabetes Mellitus and Cardiovascular Risk Assessment in Mothers
with a History of Gestational Diabetes Mellitus Based on Postpartal Expression Profile of MicroRNAs Associated with Diabetes
Mellitus and Cardiovascular and Cerebrovascular Diseases. Int. J. Mol. Sci. 2020, 21, 2437. [CrossRef]
53. Lv, Q.; Deng, J.; Chen, Y.; Wang, Y.; Liu, B.; Liu, J. Engineered Human Adipose Stem-Cell-Derived Exosomes Loaded with
miR-21-5p to Promote Diabetic Cutaneous Wound Healing. Mol. Pharm. 2020, 17, 1723–1733. [CrossRef] [PubMed]
Biology 2021, 10, 218 17 of 17
54. Dong, Y.; Wan, G.; Peng, G.; Yan, P.; Qian, C.; Li, F. Long non-coding RNA XIST regulates hyperglycemia-associated apoptosis
and migration in human retinal pigment epithelial cells. Biomed. Pharmacother. 2020, 125, 109959. [CrossRef]
55. Re, A.; Caselle, M.; Bussolino, F. MicroRNA-mediated regulatory circuits—outlook and perspectives. Phys. Biol. 2017, 14, 045001.
[CrossRef] [PubMed]
56. Michell, D.L.; Vickers, K.C. HDL and microRNA therapeutics in cardiovascular disease. Pharmacol. Ther. 2016, 168, 43–52.
[CrossRef] [PubMed]
57. Langi, G.; Szczerbinski, L.; Kretowski, A. Meta-Analysis of Differential miRNA Expression after Bariatric Surgery. J. Clin. Med.
2019, 8, 1220. [CrossRef]
58. Mendes-Silva, A.P.; Pereira, K.S.; Tolentino-Araujo, G.T.; Nicolau, E.D.S.; Silva-Ferreira, C.M.; Teixeira, A.L.; Diniz, B.S. Shared
Biologic Pathways Between Alzheimer Disease and Major Depression: A Systematic Review of MicroRNA Expression Studies.
Am. J. Geriatr. Psychiatry 2016, 24, 903–912. [CrossRef]
59. Pedretti, S.; Brulhart-Meynet, M.-C.; Montecucco, F.; Lecour, S.; James, R.W.; Frias, M.A. HDL protects against myocardial
ischemia reperfusion injury via miR-34b and miR-337 expression which requires STAT3. PLoS ONE 2019, 14, e0218432. [CrossRef]
60. Feuerborn, R.; Becker, S.; Poti, F.; Nagel, P.; Brodde, M.; Schmidt, H.; Christoffersen, C.; Ceglarek, U.; Burkhardt, R.; Nofer, J.-R.
High density lipoprotein (HDL)-associated sphinosine-1-phosphate (S1P) inhibits macrophage apoptosis by stimulating STAT3
ac-tivity and survivin expression. Atherosclerosis 2017, 257, 29–37. [CrossRef] [PubMed]
61. Frias, M.A.; James, R.W.; Gerber-Wicht, C.; Lang, U. Native and reconstituted HDL activate Stat3 in ventricular cardiomyocytes
via ERK1/2: Role of sphingosine-1-phosphate. Cardiovasc. Res. 2009, 82, 313–323. [CrossRef] [PubMed]
62. Sekine, Y.; Suzuki, K.; Remaley, A.T. HDL and sphingosine-1-phosphate activate stat3 in prostate cancer DU145 cells via ERK1/2
and S1P receptors, and promote cell migration and invasion. Prostate 2010, 71, 690–699. [CrossRef]
63. Frias, M.A.; Lang, U.; Gerber-Wicht, C.; James, R.W. Native and reconstituted HDL protect cardiomyocytes from doxorubicin-
induced apoptosis. Cardiovasc. Res. 2009, 85, 118–126. [CrossRef] [PubMed]
64. Zeng, Z.; He, W.; Jia, Z.; Hao, S. Lycopene Improves Insulin Sensitivity through Inhibition of STAT3/Srebp-1c-Mediated Lipid
Accumulation and Inflammation in Mice fed a High-Fat Diet. Exp. Clin. Endocrinol. Diabetes 2017, 125, 610–617. [CrossRef]
65. Yang, X.; Jia, J.; Yu, Z.; Duanmu, Z.; He, H.; Chen, S.; Qu, C. Inhibition of JAK2/STAT3/SOCS3 signaling attenuates atherosclerosis
in rabbit. BMC Cardiovasc. Disord. 2020, 20, 1–9. [CrossRef] [PubMed]
66. Miyazawa, K.; Miyazono, K. Regulation of TGF-β Family Signaling by Inhibitory Smads. Cold Spring Harb. Perspect. Biol. 2016, 9,
a022095. [CrossRef]
67. Wang, N.; Tall, A.R. Regulation and Mechanisms of ATP-Binding Cassette Transporter A1-Mediated Cellular Cholesterol Efflux.
Arter. Thromb. Vasc. Biol. 2003, 23, 1178–1184. [CrossRef] [PubMed]
68. Joglekar, M.V.; Joglekar, V.M.; Hardikar, A.A. Expression of islet-specific microRNAs during human pancreatic development.
Gene Expr. Patterns 2009, 9, 109–113. [CrossRef]
69. Jacovetti, C.; Rodriguez-Trejo, A.; Guay, C.; Sobel, J.; Gattesco, S.; Petrenko, V.; Saini, C.; Dibner, C.; Regazzi, R. MicroRNAs
modulate core-clock gene expression in pancreatic islets during early postnatal life in rats. Diabetology 2017, 60, 2011–2020.
[CrossRef]
70. Lee, S.; Dong, H.H. FoxO integration of insulin signaling with glucose and lipid metabolism. J. Endocrinol. 2017, 233, R67–R79.
[CrossRef]
71. Oh, H.-M.; Yu, C.-R.; Dambuza, I.; Marrero, B.; Egwuagu, C.E. STAT3 Protein Interacts with Class O Forkhead Transcription
Factors in the Cytoplasm and Regulates Nuclear/Cytoplasmic Localization of FoxO1 and FoxO3a Proteins in CD4+ T Cells. J.
Biol. Chem. 2012, 287, 30436–30443. [CrossRef] [PubMed]
